NCT05899608 is a Phase 3 clinical trial of Ivonescimab Injection in Non-Small Cell Lung Cancer, sponsored by Summit Therapeutics.

Who is sponsoring NCT05899608?

NCT05899608 is sponsored by Summit Therapeutics.

What drugs are being tested in NCT05899608?

Interventions in NCT05899608: Ivonescimab Injection, Pembrolizumab Injection.

What condition does NCT05899608 study?

NCT05899608 studies Non-Small Cell Lung Cancer.

Is NCT05899608 still recruiting?

NCT05899608 is currently recruiting now. Last updated 7 January 2026.

Last reviewed 2026-01-07 · How we verify

NCT05899608

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

Recruiting now Phase 3 Last updated 7 January 2026

What this trial tests

Phase 3 trial testing Ivonescimab Injection in Non-Small Cell Lung Cancer in 1,600 participants. Currently enrolling.

Timeline

26 October 2023

Primary endpoint
31 December 2028

31 December 2029

Quick facts

Lead sponsor	Summit Therapeutics
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	1,600
Start date	26 October 2023
Primary completion	31 December 2028
Estimated completion	31 December 2029
Sites	244 locations across France, Italy, Japan, Greece, Belgium, Serbia, Sweden, Ireland

Drugs / interventions tested

Ivonescimab Injection — full drug profile →
Pembrolizumab Injection — full drug profile →

Conditions studied

Non-Small Cell Lung Cancer — all drugs for Non-Small Cell Lung Cancer →

Sponsor

Summit Therapeutics — full company profile →

Who can join

18 and older, any sex, with Non-Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary endpoint is overall survival and progression free survival assessed by investigator. The key secondary endpoints include response and safety.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Antibodies to watch in 2024.
Crescioli S, Kaplon H, Chenoweth A, Wang L, et al · · 2024 · cited 122× · PMID 38178784 · DOI 10.1080/19420862.2023.2297450
Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors.
Frentzas S, Austria Mislang AR, Lemech C, Nagrial A, et al · · 2024 · cited 46× · PMID 38642937 · DOI 10.1136/jitc-2023-008037
Unlocking new horizons in oncology: ivonescimab's dual-target approach to anti-VEGF/PD-1(L1) therapy.
Shi F, Yang L, Gao Y, Hou Y, et al · · 2025 · cited 4× · PMID 41333457 · DOI 10.3389/fimmu.2025.1599181
Next-generation immunotherapy: igniting new hope for lung cancer.
Li MSC, Chan ALS, Mok KKS, Chan LL, et al · · 2024 · cited 3× · PMID 39649017 · DOI 10.1177/17588359241302021
Rewiring the immune response in lung cancer: current progress in bispecific antibodies, CAR-T therapy, and the rise of <i>in vivo</i> CAR-T platforms.
He L, Sun Y, Ma B, Lang G, et al · · 2026 · PMID 42093990 · DOI 10.3389/fimmu.2026.1772428
An evolving landscape: predictive and therapeutic biomarkers in advanced non-small cell lung cancer.
Fortman D, Qin A. · · 2026 · PMID 41889421 · DOI 10.3389/fonc.2026.1750153
Anti-angiogenic therapies in cancer: from endogenous inhibitors to bispecific VEGF x PD-(L)1 antibodies.
Álvarez-Vallina L, Sanz L. · · 2026 · PMID 41659853 · DOI 10.3389/fimmu.2026.1736806
LEAP-006: limits and potential of integrating anti-angiogenic agents into first-line multimodal therapy for non-squamous non-small cell lung cancer.
Santo V, Garbo E, Pecci F, Aldea M, et al · · 2025 · PMID 41522173 · DOI 10.21037/jtd-2025-aw-2034

Verify or expand the search:

Other recruiting trials for Non-Small Cell Lung Cancer

Currently open trials in the same condition.

NCT07140315 — DK222 Study at Hopkins · Phase 1 · recruiting
NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting
NCT07413757 — CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC · recruiting
NCT07460999 — Singing Training vs Usual Care 6-18 Months After Surgical Resection for Non-small Cell Lung Cancer (NSCLC) · NA · recruiting
NCT07479277 — Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC · NA · recruiting

Other Summit Therapeutics trials

Trials by the same sponsor.

NCT07228832 — Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer · Phase 3 · recruiting
NCT06396065 — Phase III Study of AK112 for NSCLC Patients · Phase 3 · active not recruiting
NCT04802837 — Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects · Phase 3 · terminated
NCT03595553 — Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05899608 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Summit Therapeutics
Last refreshed: 7 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05899608.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing